As a partner company of the Milner Therapeutics Institute,  Selcia is pleased to be attending and presenting a poster at the aforementioned symposium.

Selcia’s Associate Director of Discovery, Dr Carol Austin will present a poster “Discovery of a Potent and Orally Bioavailable Macrocyclic Cyclophilin Inhibitor by Structural Simplification of Sanglifehrin A” describing a successful integrated drug discovery collaboration between Selcia and Gilead Sciences, Inc.  The research presented will be a featured article in a forthcoming issue of the Journal of Medicinal Chemistry.

More details can be found here:

https://www.milner.cam.ac.uk/event/milner-therapeutics-symposium-2018/